Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
The nature of the pharmaceutical industry, where it is costly to discover new drugs but relatively inexpensive to produce generic versions, leads to a constant struggle between inventors and generic drug companies. Data exclusivity could disrupt this crucial supply chain, jeopardizing access to essential medicines for millions globally.
Let's personalize your content